Advanced search
Publication Cover
Biomarkers in Medicine Volume 7, 2013 - Issue 4
Submit an article Journal homepage
518
Views
0
CrossRef citations to date
0
Altmetric
General Content - Editorial

The significance of MEN1 mutations in Pituitary Carcinomas

Thomas Cunya Department of Endocrinology, University Hospital of Nancy, Brabois, Allée de Morvan, France and Aix-Marseille University,CRN2M, UMR 7286-CNRS,Marseille,France
&
Anne Barlierb AP-HM, Hôpital de la Conception, Laboratoire de Biologie Moléculaire, Bd Baille, 13385 Marseille, France and Aix-Marseille University,CRN2M, UMR 7286-CNRS,Marseille,France.Correspondence[email protected]
Pages 567-569 | Published online: 02 Aug 2013

References

  • Thakker RV , NeweyPJ, WallsGVet al. Clinical practice guidelines for multiple endocrine neoplasia type 1 (MEN1). J. Clin. Endocrinol. Metab. 97(9), 2990–3011 (2012).
  • Chandrasekharappa SC , GuruSC, ManickamPet al. Positional cloning of the gene for multiple endocrine neoplasia-type 1. Science 276(5311), 404–407 (1997).
  • Agarwal SK , KennedyPA, ScacheriPCet al. Menin molecular interactions: insights into normal functions and tumorigenesis. Horm. Metab. Res. 37(6), 369–374 (2005).
  • Lemos MC , ThakkerRV. Multiple endocrine neoplasia type 1 (MEN1): analysis of 1336 mutations reported in the first decade following identification of the gene. Hum. Mutat.29(1), 22–32 (2008).
  • Thevenon J , BourredjemA, FaivreLet al. Higher risk of death among MEN1 patients with mutations in the JunD interacting domain: a Groupe d‘etude des Tumeurs Endocrines (GTE) cohort study. Hum. Mol. Genet. 22(10), 1940–1948 (2013).
  • Syro LV , ScheithauerBW, KovacsKet al. Pituitary tumors in patients with MEN1 syndrome. Clinics (Sao Paulo) 67(Suppl. 1), 43–48 (2012).
  • Elston MS , McDonaldKL, Clifton-BlighRJ, RobinsonBG. Familial pituitary tumor syndromes. Nat. Rev. Endocrinol.5(8), 453–461 (2009).
  • Nunes VS , SouzaGL, PeroneD, CondeSJ, NogueiraCR. Frequency of multiple endocrine neoplasia type 1 in a group of patients with pituitary adenoma: genetic study and familial screening.Pituitary doi:10.1007/s11102-013-0462-8 (2013) (Epub ahead of print).
  • Goudet P , Bonithon-KoppC, MuratAet al. Gender-related differences in MEN1 lesion occurrence and diagnosis: a cohort study of 734 cases from the Groupe d‘etude des Tumeurs Endocrines. Eur. J. Endocrinol. 165(1), 97–105 (2011).
  • Delemer B . MEN1 and pituitary adenomas. Ann. Endocrinol. (Paris)73(2), 59–61 (2012).
  • Vergès B , BoureilleF, GoudetPet al. Pituitary disease in MEN type 1 (MEN1): data from the France–Belgium MEN1 multicenter study. J. Clin. Endocrinol. Metab. 87(2), 457–465 (2002).
  • Trouillas J , Labat-MoleurF, SturmNet al. Pituitary tumors and hyperplasia in multiple endocrine neoplasia type 1 syndrome (MEN1): a case–control study in a series of 77 patients versus 2509 non-MEN1 patients. Am. J. Surg. Pathol. 32(4), 534–543 (2008).
  • Cuny T , PertuitM, Sahnoun-FathallahMet al. Genetic analysis in young patients with sporadic pituitary macroadenomas: besides AIP don‘t forget MEN1 genetic analysis. Eur. J. Endocrinol. 168(4), 533–541 (2013).
  • Raverot G , CastinettiF, JouanneauEet al. Pituitary carcinomas and aggressive pituitary tumours: merits and pitfalls of temozolomide treatment. Clin. Endocrinol. (Oxf) 76(6), 769–775 (2012).
  • Mete O , EzzatS, AsaSL. Biomarkers of aggressive pituitary adenomas. J. Mol. Endocrinol.49(2), R69–R78 (2012).
  • Philippon M , MorangeI, BarrieMet al. Long-term control of a MEN1 prolactin secreting pituitary carcinoma after temozolomide treatment. Ann. Endocrinol. (Paris) 73(3), 225–229 (2012).
  • Scheithauer BW , KovacsK, NoseVet al. Multiple endocrine neoplasia type 1-associated thyrotropin-producing pituitary carcinoma: report of a probable de novo example. Hum. Pathol. 40(2), 270–278 (2009).
  • Vroonen L , Jaffrain-ReaML, PetrossiansPet al. Prolactinomas resistant to standard doses of cabergoline: a multicenter study of 92 patients. Eur. J. Endocrinol. 167(5), 651–662 (2012).
  • Walls GV , LemosMC, JavidMet al. MEN1 gene replacement therapy reduces proliferation rates in a mouse model of pituitary adenomas. Cancer Res.72(19), 5060–5068 (2012).
  • Trouillas J , RoyP, SturmNet al. A new prognostic clinicopathological classification of pituitary adenomas: a multicentric case–control study of 410 patients with 8 years post-operative follow-up. Acta Neuropathol. 126(1), 123–135 (2013).

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.